Full Length Research Paper
References
|
Amouri I, Abbes S, Sellami H, Makni F, Sellami A, Ayadi A (2010). Vulvovaginal candidiasis: A review. Journal of Medical Mycology 20(2):108-115. |
|
|
Arslan S, Koç AN, Åžekerci AE, Tanriverdi F, Sav H, Aydemir G, Diri H (2016). Genotypes and virulence factors of Candida species isolated from oral cavities of patients with type 2 diabetes mellitus. Turkish Journal of Medical Sciences 46(1):18-27. |
|
|
Badillet G, Bievre C, Gueho E (1987). Champignons contaminants des cultures. Champignons opportunistes. Atlas clinique et biologique Varia; 2:132- 216. |
|
|
Bagg J, Petrina Sweeney M, Andrew N. Davies, Margaret S. Jackson, Susan B (2005). Voriconazole susceptibility of yeasts isolated from the mouths of patients with advanced cancer. Journal of Medical Microbiology 54(10): 959-964. |
|
|
Bailly C, Vagner O, Aho S, Lopez J, Caillot D, Cuisenier B, Fussy A, Chavanet P, Freysz M, Bonnin A, Camerlynck P (1995). In vitro fluconazole susceptibility of 164 Candida spp. strains isolated from blood cultures or oropharynx in patients treated or not treated prophylactically with fluconazole. Médecine et Maladies Infectieuses 25(8-9): 919-926. |
|
|
Bernal S, Martin Mazuelos E, Garcia M, Aller A I, Martinez MA, and Gutiérrez MJ (1996). Evaluation of CHROMagar Candida Medium For the Isolation and Presumptive Identification of Species of Candida of Clinical Importance. Diagnostic Microbiology and Infectious Disease 24(4):201-204. |
|
|
Berry AJ, Rinaldi MG, Graybill JR (1992). Use of high-dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS. Antimicrobial Agents and Chemotherapy 36(3):690-692. |
|
|
Bonouman-Ira V, Angora E , Djohan V, Vanga-Bosson H, Sylla-Thanon K, Beourou S, Touré AO, Faye-Ketté H, Dosso M, Koné M (2011). Resistance of Candida no albicans in Abidjan in 2011. Revue Bio-Africa 9:27-31. |
|
|
Calderone RA, Fonzi WA (2001). Virulence factors of Candida albicans. Trends Microbiology 9(7):327-335. |
|
|
Cleveland AA, Harrison LH , Farley M M ,Hollick R ,Stein,B, Chiller TM, Lockhart SR,, Park BJ (2015). Declining incidence of candidemia and the shifting epidemiology of Candida resistance in two US metropolitan areas, 2008-2013: results from population-based surveillance. PLoS ONE 10(3): e0120452. |
|
|
Chryssanthou E (2001). Trends In antifungal susceptibility among Swedish Candida species bloodstream isolates from 1994 to 1998. |
|
|
Comparison of the E-test and the Sensititre Yeast One Colorimetric Antifungal Panel With the NCCLS M27A reference method. Journal of Clinical Microbiology 39: 4181-4183. |
|
|
Dannaoui E, Desnos-Ollivier M, Garcia-Hermoso D, Grenouillet F, Cassaing S, Baixench MT, Bretagne S, Dromer F, Lortholary O, French Mycoses Study Group (2012). Candida spp. with acquired echinocandin resistance, France, 2004-2010. Emerging Infectious Diseases 18:86-90. |
|
|
Djohan V, Angora KE, Vanga-Bosson AH, Konaté A, Kassi FK. Yavo W, Kiki-Barro PC, et col (2011). In vitro susceptibility of vaginal Virulence factors of Candida albicans. Trends Microbiology to antifungal drugs in Abidjan (Cote d'Ivoire). Journal of Medical Mycology 22(2):129-133. |
|
|
El-Din S, Reynolds TM, Ashbee HR, Barton RC, Evans EG (2001). An Investigation into the pathogenesis of vulvovaginal candidiasis. Sexually Transmitted Infections 77:179-183. |
|
|
Gonsu Kamga H, Kechia Agem FA, Tegankam D, Toukam M, Sando Z, Moyou Somo R (2014). Antifungal susceptibility patterns among the clinical isolates of Candida spp. in digestive candidiasis in the HIV-positive subjects. Health Sciences and Diseases 15(3). |
|
|
Godoy P, Tiraboschi IN, Severo LC, Bustamante B, Calvo B, Almeida LP, da Matta DA, Colombo AL (2003). Species distribution and antifungal susceptibility profile of Candida spp. Bloodstream isolates from Latin American hospitals. Memórias do Instituto Oswaldo Cruz 98(3):401-405. |
|
|
Guillot J, Dannaoui E (2015). Resistance to antifungal drugs: importance in human and veterinary medicine. Bulletin de l'Académie Vétérinaire de France Tome 168(4):314-319. |
|
|
Hoyer LL, Payne TL, Bell M, Myers AM, Scherer S (1998). Candida albicans ALS3 and insights into the nature of the ALS gene family. Current Genetics 33:451-459. |
|
|
Jin-Sol L, Jong HS, Kyungwon L, Mi-Na K, Bo-Moon S, Young U (2007). Species distribution and susceptibility to azole antifungals of Candida bloodstream isolates from eight university hospitals in Korea. Yonsei Medical Journal 48:779-86. |
|
|
Karkowska-Kuleta J, Rapala-Kozik M, Kozik A (2009). Fungi pathogenic to humans: Molecular bases of virulence of Candida albicans, Cryptococcus neoformans and Aspergillus fumigatus. Acta Biochimica Polonica 56:211-224. |
|
|
Kechia FA, Dohbit JS, Kouotou EA, Iwewe SY, Dzoyem JP, Mbopuwouo NM, Monamele CG, Moyou SR (2015). Epidemiologic and mycological pattern of vulvo-vaginal candidiasis in pregnancy in Yaounde. Health Sciences and Diseases 16(4):1-6. |
|
|
Khan ZU, Chandy R, Metwali KE (2003). Candida albicans strain carriage in patients and nursing staff of an intensive care unit: A study of morphotypes and resistotypes. Mycoses 46:476-486. |
|
|
Khosravi AR, Shokri H, Mansouri P, Katiraee F, Ziglari T (2008). Candida species isolated from nails and their in vitro susceptibility to antifungal drugs in the department of dermatology (University of Tehran, Iran). Journal of Medical Mycology 18:210-215. |
|
|
Klepser ME (2001). Antifungal resistance among Candida species. Pharmacotherapy 21:124-132. |
|
|
Klingspor L, Tortorano AM, Peman J, Willinger B, Hamal P, Sendid B, Velegraki A, Kibbler C, Meis JF, Sabino R, Ruhnke M, Arikan-Akdagli S, Salonen J, Dóczi I (2015). Invasive Candida infections in surgical patients in intensive care units: A prospective, multicentre survey initiated by the European Confederation of Medical Mycology (ECMM) (2006-2008). Clinical Microbiology and Infection 21(1):87.e1-87.e10. |
|
|
Kronvall G, Karlsson I (2001). Fluconazole and voriconazole multidisk testing of Candida species for disk test calibration and MIC estimation. Journal of Clinical Microbiology 39(4):1422-1428 |
|
|
Lacroix C, Gicquel A, Sendid B, Meyer J, Accoceberry I, Francçois N, Morio F, Desoubeaux G, Chandenier J, Kauffmann-Lacroix C, Hennequin C, Guitard J, Nassif X, Bougnoux M-E (2014). Evaluation of two matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) systems for the identification of Candida species. Clinical Microbiology and Infection 20(2):153-158. |
|
|
Lindsay G, Steven K, Yvonne R, Adrian M, Patrick R (2010). Evaluation of Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry for Identification of Clinically Important Yeast Species. Journal of Clinical Microbiology 48(10):3482-3486. |
|
|
Nasrollahi Z, Yadegari MH, Roudbar MS, Roudbary M, Hosseini PM, Nikoomanesh F, Bazl MR (2015). Fluconazole Resistance Candida albicans in Females With Recurrent Vaginitis and Pir1 Overexpression. Jundishapur Journal of Microbiology 8(9):e21468. |
|
|
National Committee for Clinical Laboratory Standards (1997). Reference Method for Broth dilution. Antifungal Susceptibility Testing of Yeasts; Approved Standard. Document M27-A 17, 1/29. 22(15). |
|
|
Nocon C (2013). Evaluation des performances du spectre de masse MALDI-TOF MICROFLEX LT Bruker comparées à celle du spectre VITEK BIOMERIEUX et demarche d'accréditation. https://pepite-depot.univ-lille2.fr/nuxeo/site/esupversions/f6ce20e2-6556-4e88-a7d7-7e01875b040 |
|
|
Odds FC, Bernaerts R (1994). CHROMagar Candida, a new differential isolation medium for presumptive identification of clinically important Candida species. Journal of Clinical Microbiology 32:1923-1929. |
|
|
Panizo MM, Reviakina V, Dolande M, Selgrad S (2009). Candida spp in vitro susceptibility proï¬le to four antifungal agents. Resistance surveillance study in Venezuelan strains. Journal of Medical Mycology 47:137-143. |
|
|
Pfaller MA, Messer SA, Hollis RJ, Jones RN, Diekema DJ (2002). In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrobial Agents and Chemotherapy 46(6):1723-1727. |
|
|
Regli P, Blancard A, Goudard M, Moulin-Traffort L, Sarzier JM, Quilici M (1992). Evaluation in vitro susceptibility of yeasts for fluconazole. Pathologie Biologie 40:500-506. |
|
|
Roman E, Arana DM, Nombela C, Alonso-Monge R, Pla J (2007). MAP kinase pathways as regulators of fungal virulence. Trends in Microbiology 15:181-190. |
|
|
Ruhnke M, Eigler A, Engelmann E, Geiseler B, Trautmann M (1994). Correlation between antifungal susceptibility testing of Candida isolates from patients with HIV infection and clinical results after treatment with fluconazole. Infection 22:72-75. |
|
|
Sandra SR, Rudolph PG, Shawn AM, Richard JH, Daniel JD, Michael A (2005). Antifungal susceptibilities of Candida Species causing vulvovaginitis and epidemiology of recurrent cases. Journal of Clinical Microbiology 43:2155-2162. |
|
|
Saporiti AM, Gomez D, Levalle S, Galeano M, Davel G, Vivot W, Et al., (2001). Vaginal candidiasis: etiology and sensitivity proï¬le to antifungal agents in clinical use. Revista Argentina de Microbiología 33:217-222. |
|
|
Schaller M, Borelli C, Korting HC, Hube B (2005). Hydrolytic enzymes as virulence factors of Candida albicans. Mycoses 48:365-377. |
|
|
Sharifzadeh A, Khosravi AR, Shokri H, Asadi Jamnani F, Hajiabdolbaghi, M, Ashraï¬ Tamami I (2013). Oral microflora and their relation to risk factors in HIV+ patients with oropharyngeal candidiasis. Journal of Medical Mycology 23(2):105-12. |
|
|
Skrodeniene E Dambrauskiene A, Vitkauskiene A (2006). Susceptibility of yeasts to antifungal agents in Kaunas University of Medicine Hospital. Medicina (Kaunas) 42:294-299. |
|
|
Sobel JD, Wiesenfeld HC, Martens M, Danna P, Hooton TM, Rompalo A, Malcolm Sperling, Charles Livengood 3rd, Benson Horowitz, James Von Thron, Libby Edwards, Helene Panzer, Teng-Chiao Chu (2004). Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. New England Journal of Medicine 351:876-883. |
|
|
Sobel JD, Zervos M, Reed BD, Hooton T, Soper D, Nyirjesy P, Heine MW, Willems J, Panzer H (2003). Fluconazole Susceptibility of vaginal isolates obtained from women with complicated Candida vaginitis: Clinical implications. Antimicrobial Agents and Chemotherapy 47:34-38. |
|
|
St-Germain G, Laverdière M, Pelletier R, Bourgault AM, Libman M, Lemieux C, Noël G (2001). Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: Results of a 2-Year (1996 to 1998) Multicenter Surveillance Study in Quebec, Canada. Journal of Clinical Microbiology 39(3):949-953. |
|
|
Tortorano AM, Rigoni AL, Biraghi E, Prigitano A, Viviani MA, FIMUA-ECMM Candidaemia Study Group (2003). The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: Antifungal susceptibility patterns of 261 non-Candida albicans isolates from blood. The Journal of Antimicrobial Chemotherapy 52:679-682. |
|
|
Vandeputte P, Ferrari S, AlixT Coste (2012). Antifungal resistance and new strategies to control fungal. International Journal of Microbiology 2012:26p. |
|
|
Whaley SG, Berkow EL, Rybak JM, Nishimoto AT, Barker KS, Rogers PD (2017). Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species. Frontiers Microbiology 7:2173. |
|
|
Zhang L, Wang H, Xiao M, Kudinha T, Mao LL, Zhao HR, Kong F, Xu YC (2014). The widely used ATB FUNGUS 3 automated readings in China and its misleading high MICs of Candida spp. to azoles: Challenges for developing countries' clinical microbiology labs. PLoS One 2014;9:e114004. |
|
Copyright © 2024 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0
